2022
The Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome
Chen A, Seifer D, Tal R. The Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome. 2022, 449-487. DOI: 10.1007/978-3-030-92589-5_23.Peer-Reviewed Original ResearchPolycystic ovarian syndromeOvulatory dysfunctionGrowth factorOvarian syndromePathophysiology of PCOSAngiogenic factorsAbnormal endometrial receptivityPCOS animal modelsOvarian hyperstimulation syndromeReproductive-age womenMenstrual cycle functionVascular endothelial growth factorNormal follicular developmentComplex endocrine disorderPlatelet-derived growth factorBasic fibroblast growth factorEndothelial growth factorFibroblast growth factorAngiogenesis dysfunctionHyperstimulation syndromeAngiogenic imbalancePCOS patientsPCOS managementPolycystic ovariesAngiogenesis-based therapiesChapter 23 Polycystic ovarian syndrome and reproductive failure
Duero J, Tal R. Chapter 23 Polycystic ovarian syndrome and reproductive failure. 2022, 351-378. DOI: 10.1016/b978-0-323-90805-4.00009-2.ChaptersPolycystic ovarian syndromeInsulin resistanceOvarian syndromeEndometrial receptivityUterine abnormalitiesReproductive dysfunctionPathophysiology of PCOSRecurrent pregnancy lossReproductive-age womenAbnormal follicular developmentRisk of obesityComplex endocrine disorderEndometrial gene expressionMajority of womenType II diabetesPregnancy complicationsPolycystic ovariesPreterm birthPlacental dysfunctionChronic inflammationClinical manifestationsEndocrine disordersImplantation failurePregnancy lossCardiovascular disease
2015
The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome
Tal R, Seifer DB, Arici A. The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome. Seminars In Reproductive Medicine 2015, 33: 195-207. PMID: 26036901, DOI: 10.1055/s-0035-1552582.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeGrowth factorOvarian syndromePathophysiology of PCOSAngiogenic factor imbalanceOvarian hyperstimulation syndromeCommon endocrine disorderVascular endothelial growth factorPlatelet-derived growth factorBasic fibroblast growth factorMultiple angiogenic factorsEndothelial growth factorFibroblast growth factorHyperstimulation syndromeOvulatory dysfunctionStromal vascularityAnovulatory infertilityPolycystic ovariesEndocrine disordersReproductive ageTreatment strategiesFollicular growthOvarian angiogenesisAngiogenic factorsCorpus luteum
2014
Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2013
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation
Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility And Sterility 2013, 100: 538-543. PMID: 23684116, DOI: 10.1016/j.fertnstert.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CDCase-Control StudiesEndoglinFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromeReceptors, Cell SurfaceSperm Injections, IntracytoplasmicTransforming Growth Factor beta1UltrasonographyYoung AdultConceptsPolycystic ovarian syndromeSerum soluble endoglinDay of hCGSoluble endoglinFollicular fluidTGF-β1Oocyte retrievalOvarian stimulationHCG administrationControl womenDay 3Pathogenesis of PCOSNon-PCOS control groupProspective case-control studyNon-PCOS controlsSerum TGF-β1Non-PCOS womenPolycystic ovary syndromeTGF-β1 levelsReproductive technology unitCase-control studyGrowth factor-β1Day of retrievalOvarian hyperstimulationOvarian syndrome
2012
Preeclampsia-associated soluble endoglin (sENG) is decreased in polycystic ovarian syndrome (PCOS) leading to transforming growth factor (TGF)-B1 dysregulation during controlled ovarian stimulation
Tal R, Seifer D, Shohat-Tal A, Grazi R, Malter H. Preeclampsia-associated soluble endoglin (sENG) is decreased in polycystic ovarian syndrome (PCOS) leading to transforming growth factor (TGF)-B1 dysregulation during controlled ovarian stimulation. Fertility And Sterility 2012, 98: s84. DOI: 10.1016/j.fertnstert.2012.07.304.Peer-Reviewed Original ResearchPolycystic ovarian syndromeSoluble endoglinOvarian stimulationOvarian syndromeGrowth factorPreeclampsiaSyndromeEndoglin